泓博医药 (301230.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

54.1x

Market Cap

CNY 6.12B

MomentumView details →

1D Return

−5.26%

YTD Return

−0.87%

RSI (14)

40.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

54.1x

Market Cap

CNY 6.12B

RSI (14)

40.6

MomentumView details →

1D Return

−5.26%

YTD Return

−0.87%

ProfitabilityView details →

Gross Margin

28.30%

Net Margin

6.67%

EBITDA Margin

14.49%

ROE (TTM)

4.48%

ROA (TTM)

3.50%

Asset Turnover

0.53x

GrowthView details →

Revenue YoY

+18.52%

EPS YoY

+81.58%

FCF YoY

+512.78%

Revenue CAGR 3Y

+12.86%

EPS CAGR 3Y

−31.85%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.13x

Current Ratio

3.76x

Quick Ratio

3.17x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

691.21M

Net Income (TTM)

46.10M

Op. CF (TTM)

167.14M

Latest newsMore news →

Hongbo Medicine announced its first-half 2026 results: revenue of 364 million yuan, up 3.31% year-on-year; net profit attributable to shareholders of 28.7294 million yuan, up 16.02%; non-recurring net profit of 6.4603 million yuan, down 67.95%.9d ago

Similar companies

苏交科300284.SZ 广东建科301632.SZ 尤安设计300983.SZ 博济医药300404.SZ 中机认检301508.SZ 钢研纳克300797.SZ

Latest newsMore news →

Hongbo Medicine announced its first-half 2026 results: revenue of 364 million yuan, up 3.31% year-on-year; net profit attributable to shareholders of 28.7294 million yuan, up 16.02%; non-recurring net profit of 6.4603 million yuan, down 67.95%.9d ago